Skip to main content

I6T-MC-AMAM A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

NCT03926130

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Eli Lilly

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions:
How safe mirikizumab is and whether you might have any side effects when you take it.
How effective mirikizumab is as a treatment for Crohn’s disease when other medications may not work.

How mirikizumab compares to ustekinumab or placebo.

Mirikizumab is “Investigational”, which means that it has not been approved for routine clinical use or for the use described in this study by the United States Food and Drug Administration (FDA). The FDA is allowing the use of this drug for research.

This study is currently enrolling.